Greatmark Investment Partners Inc. Boosts Holdings in Johnson & Johnson $JNJ

Greatmark Investment Partners Inc. lifted its stake in Johnson & Johnson (NYSE:JNJ) by 2.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 120,464 shares of the company’s stock after buying an additional 3,166 shares during the quarter. Johnson & Johnson makes up 2.3% of Greatmark Investment Partners Inc.’s holdings, making the stock its 16th largest holding. Greatmark Investment Partners Inc.’s holdings in Johnson & Johnson were worth $18,401,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Apexium Financial LP raised its position in shares of Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after purchasing an additional 2,310 shares during the last quarter. Avanza Fonder AB raised its position in shares of Johnson & Johnson by 2.9% in the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after purchasing an additional 6,566 shares during the last quarter. Joel Isaacson & Co. LLC raised its position in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after purchasing an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after purchasing an additional 4,816 shares during the last quarter. Finally, Klingman & Associates LLC raised its position in Johnson & Johnson by 13.4% in the 1st quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock worth $2,817,000 after buying an additional 2,005 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Down 0.3%

Shares of NYSE:JNJ opened at $192.31 on Friday. The stock has a 50 day moving average of $181.99 and a 200 day moving average of $165.84. The company has a market cap of $463.15 billion, a PE ratio of 18.56, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday. Finally, UBS Group boosted their target price on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.